Exact Sciences Corporation (EXAS)
USD 42.12
(-0.34%)
USD 42.12
(-0.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -215.01 Million USD | 62.77% |
| 2022 | -577.54 Million USD | 30.87% |
| 2021 | -835.46 Million USD | -49.63% |
| 2020 | -558.35 Million USD | -138.83% |
| 2019 | -233.78 Million USD | -46.6% |
| 2018 | -159.47 Million USD | -34.79% |
| 2017 | -118.31 Million USD | 30.0% |
| 2016 | -169.01 Million USD | -6.25% |
| 2015 | -159.06 Million USD | -58.22% |
| 2014 | -100.53 Million USD | -115.01% |
| 2013 | -46.76 Million USD | 11.17% |
| 2012 | -52.64 Million USD | -82.64% |
| 2011 | -28.82 Million USD | -143.73% |
| 2010 | -11.82 Million USD | -28.43% |
| 2009 | -9.2 Million USD | 7.67% |
| 2008 | -9.97 Million USD | 22.37% |
| 2007 | -12.84 Million USD | 9.32% |
| 2006 | -14.16 Million USD | 9.38% |
| 2005 | -15.63 Million USD | 18.55% |
| 2004 | -19.19 Million USD | 33.44% |
| 2003 | -28.83 Million USD | 6.51% |
| 2002 | -30.84 Million USD | -17.95% |
| 2001 | -26.15 Million USD | -157.75% |
| 2000 | -10.14 Million USD | -92.78% |
| 1999 | -5.26 Million USD | -30.89% |
| 1998 | -4.02 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -106.69 Million USD | -57.27% |
| 2024 Q2 | -21.9 Million USD | 79.47% |
| 2024 Q3 | 3.1 Million USD | -79.88% |
| 2023 FY | -215.01 Million USD | 62.77% |
| 2023 Q4 | -67.84 Million USD | -1090.52% |
| 2023 Q1 | -77.02 Million USD | 33.29% |
| 2023 Q2 | -76.92 Million USD | 0.12% |
| 2023 Q3 | 6.84 Million USD | 108.9% |
| 2022 Q2 | -152.99 Million USD | 13.57% |
| 2022 Q4 | -115.45 Million USD | 12.61% |
| 2022 FY | -577.54 Million USD | 30.87% |
| 2022 Q1 | -177.01 Million USD | 20.07% |
| 2022 Q3 | -132.11 Million USD | 13.65% |
| 2021 FY | -835.46 Million USD | -49.63% |
| 2021 Q1 | -300.54 Million USD | 27.63% |
| 2021 Q2 | -171.66 Million USD | 42.88% |
| 2021 Q3 | -162.02 Million USD | 5.62% |
| 2021 Q4 | -221.45 Million USD | -36.68% |
| 2020 Q3 | -203.33 Million USD | -203.44% |
| 2020 FY | -558.35 Million USD | -138.83% |
| 2020 Q4 | -415.3 Million USD | -104.25% |
| 2020 Q2 | -67 Million USD | 18.65% |
| 2020 Q1 | -82.37 Million USD | 14.29% |
| 2019 FY | -233.78 Million USD | -46.6% |
| 2019 Q4 | -96.1 Million USD | -169.51% |
| 2019 Q3 | -35.66 Million USD | -5.44% |
| 2019 Q1 | -68.19 Million USD | -38.28% |
| 2019 Q2 | -33.82 Million USD | 50.41% |
| 2018 Q2 | -32.7 Million USD | 10.47% |
| 2018 Q1 | -36.52 Million USD | -57.91% |
| 2018 Q3 | -40.92 Million USD | -25.15% |
| 2018 Q4 | -49.31 Million USD | -20.5% |
| 2018 FY | -159.47 Million USD | -34.79% |
| 2017 Q1 | -35.49 Million USD | 5.88% |
| 2017 FY | -118.31 Million USD | 30.0% |
| 2017 Q4 | -23.13 Million USD | 18.58% |
| 2017 Q3 | -28.41 Million USD | 9.57% |
| 2017 Q2 | -31.41 Million USD | 11.47% |
| 2016 Q2 | -45.13 Million USD | 5.74% |
| 2016 Q3 | -38.28 Million USD | 15.18% |
| 2016 Q1 | -47.88 Million USD | -18.47% |
| 2016 FY | -169.01 Million USD | -6.25% |
| 2016 Q4 | -37.71 Million USD | 1.5% |
| 2015 Q3 | -43.27 Million USD | -9.92% |
| 2015 Q4 | -40.42 Million USD | 6.59% |
| 2015 Q2 | -39.36 Million USD | -9.31% |
| 2015 Q1 | -36.01 Million USD | -10.52% |
| 2015 FY | -159.06 Million USD | -58.22% |
| 2014 Q1 | -16.17 Million USD | -31.89% |
| 2014 FY | -100.53 Million USD | -115.01% |
| 2014 Q4 | -32.58 Million USD | -1.16% |
| 2014 Q3 | -32.2 Million USD | -64.58% |
| 2014 Q2 | -19.57 Million USD | -20.97% |
| 2013 Q2 | -12.35 Million USD | -13.34% |
| 2013 Q3 | -11.24 Million USD | 8.94% |
| 2013 Q1 | -10.89 Million USD | 22.4% |
| 2013 Q4 | -12.26 Million USD | -9.06% |
| 2013 FY | -46.76 Million USD | 11.17% |
| 2012 Q3 | -13 Million USD | 12.64% |
| 2012 FY | -52.64 Million USD | -82.64% |
| 2012 Q2 | -14.89 Million USD | -39.13% |
| 2012 Q4 | -14.04 Million USD | -7.95% |
| 2012 Q1 | -10.7 Million USD | -7.71% |
| 2011 Q3 | -7.84 Million USD | -18.08% |
| 2011 FY | -28.82 Million USD | -143.73% |
| 2011 Q2 | -6.64 Million USD | -50.89% |
| 2011 Q1 | -4.4 Million USD | -15.15% |
| 2011 Q4 | -9.93 Million USD | -26.69% |
| 2010 Q1 | -2.12 Million USD | -14.45% |
| 2010 Q3 | -3.39 Million USD | -36.71% |
| 2010 Q4 | -3.82 Million USD | -12.57% |
| 2010 FY | -11.82 Million USD | -28.43% |
| 2010 Q2 | -2.48 Million USD | -17.0% |
| 2009 Q3 | -1.07 Million USD | 55.96% |
| 2009 FY | -9.2 Million USD | 7.67% |
| 2009 Q4 | -1.85 Million USD | -72.4% |
| 2009 Q2 | -2.44 Million USD | 36.92% |
| 2009 Q1 | -3.87 Million USD | -82.95% |
| 2008 Q3 | -3.05 Million USD | -40.94% |
| 2008 Q4 | -2.11 Million USD | 30.59% |
| 2008 FY | -9.97 Million USD | 22.37% |
| 2008 Q1 | -2.64 Million USD | 37.1% |
| 2008 Q2 | -2.16 Million USD | 18.09% |
| 2007 Q4 | -4.2 Million USD | 4.65% |
| 2007 FY | -12.84 Million USD | 9.32% |
| 2007 Q1 | -2.17 Million USD | 20.01% |
| 2007 Q2 | -2.06 Million USD | 5.32% |
| 2007 Q3 | -4.4 Million USD | -113.52% |
| 2006 Q4 | -2.72 Million USD | 19.95% |
| 2006 FY | -14.16 Million USD | 9.38% |
| 2006 Q1 | -4.48 Million USD | -48.77% |
| 2006 Q2 | -3.55 Million USD | 20.58% |
| 2006 Q3 | -3.4 Million USD | 4.38% |
| 2005 Q4 | -3.01 Million USD | 15.84% |
| 2005 FY | -15.63 Million USD | 18.55% |
| 2005 Q3 | -3.57 Million USD | 15.03% |
| 2005 Q2 | -4.21 Million USD | 12.81% |
| 2005 Q1 | -4.83 Million USD | -1.6% |
| 2004 Q1 | -5.4 Million USD | 6.95% |
| 2004 Q2 | -4.45 Million USD | 17.71% |
| 2004 Q4 | -4.75 Million USD | -3.82% |
| 2004 Q3 | -4.58 Million USD | -2.9% |
| 2004 FY | -19.19 Million USD | 33.44% |
| 2003 Q1 | -8.05 Million USD | -11.61% |
| 2003 FY | -28.83 Million USD | 6.51% |
| 2003 Q2 | -8.01 Million USD | 0.5% |
| 2003 Q3 | -6.96 Million USD | 13.05% |
| 2003 Q4 | -5.81 Million USD | 16.54% |
| 2002 Q1 | -7.86 Million USD | -10.57% |
| 2002 Q4 | -7.21 Million USD | 5.9% |
| 2002 Q2 | -8.1 Million USD | -3.12% |
| 2002 FY | -30.84 Million USD | -17.95% |
| 2002 Q3 | -7.66 Million USD | 5.44% |
| 2001 Q2 | -6.51 Million USD | -5.39% |
| 2001 Q4 | -7.1 Million USD | -11.92% |
| 2001 Q1 | -6.17 Million USD | 0.0% |
| 2001 FY | -26.15 Million USD | -157.75% |
| 2001 Q3 | -6.35 Million USD | 2.43% |
| 2000 FY | -10.14 Million USD | -92.78% |
| 1999 FY | -5.26 Million USD | -30.89% |
| 1998 FY | -4.02 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -120.849% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -1862.99% |
| Aspira Women's Health Inc. | -18.85 Million USD | -1040.526% |
| Biodesix, Inc. | -41.34 Million USD | -420.081% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -8190.137% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -2596.674% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -2596.674% |
| Bionano Genomics, Inc. | -215.24 Million USD | 0.108% |
| CareDx, Inc | -101.9 Million USD | -111.003% |
| Check-Cap Ltd. | -19.28 Million USD | -1014.803% |
| Castle Biosciences, Inc. | -67.97 Million USD | -216.301% |
| DarioHealth Corp. | -56.18 Million USD | -282.659% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -195.773% |
| Guardant Health, Inc. | -564.72 Million USD | 61.926% |
| ICON Public Limited Company | 956.15 Million USD | 122.487% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 119.598% |
| Illumina, Inc. | -1.06 Billion USD | 79.887% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -1990.911% |
| iSpecimen Inc. | -11.16 Million USD | -1825.018% |
| Standard BioTools Inc. | -76.6 Million USD | -180.695% |
| MDxHealth SA | -27.32 Million USD | -686.812% |
| 23andMe Holding Co. | -321.35 Million USD | 33.092% |
| Medpace Holdings, Inc. | 336.82 Million USD | 163.835% |
| Myriad Genetics, Inc. | -123.7 Million USD | -73.817% |
| Mainz Biomed B.V. | -26.64 Million USD | -706.96% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -1943.698% |
| NeoGenomics, Inc. | -107.73 Million USD | -99.573% |
| Neogen Corporation | 58.66 Million USD | 466.521% |
| Inotiv, Inc. | -81.46 Million USD | -163.948% |
| Natera, Inc. | -446.24 Million USD | 51.817% |
| OpGen, Inc. | -15.68 Million USD | -1270.509% |
| OPKO Health, Inc. | -157.02 Million USD | -36.932% |
| Psychemedics Corporation | -2.92 Million USD | -7260.904% |
| Prenetics Global Limited | -52.51 Million USD | -309.441% |
| Prenetics Global Limited | -52.51 Million USD | -309.441% |
| Precipio, Inc. | -7.62 Million USD | -2721.68% |
| Personalis, Inc. | -109.93 Million USD | -95.579% |
| RadNet, Inc. | 98.69 Million USD | 317.851% |
| Sera Prognostics, Inc. | -39.82 Million USD | -439.946% |
| Sotera Health Company | 276.69 Million USD | 177.708% |
| Neuronetics, Inc. | -30.55 Million USD | -603.711% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -4847.354% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -4847.354% |
| Trinity Biotech plc | -27.04 Million USD | -695.016% |
| T2 Biosystems, Inc. | -49.66 Million USD | -332.933% |
| Twist Bioscience Corporation | -220.83 Million USD | 2.635% |
| Exagen Inc. | -22.83 Million USD | -841.507% |